Latest / The Meaning of Health Podcast / Ep 153 - Equitable Access and the ZOLADEX Crisis with Dr Monica Tang & Prof Sallie Pearson
Transcript
- 0:00SPEAKER_02: The Meaning of Health podcast acknowledges the traditional
- 0:03SPEAKER_03: custodians of the land
- 0:04SPEAKER_03: where the podcast is produced, Wodchuk Noongar people.
- 0:08SPEAKER_03: We pay our respects to elders past,
- 0:10SPEAKER_03: present and all Aboriginal and Torres Strait Islander people listening.
- 0:15SPEAKER_03: I think in Australia,
- 0:16SPEAKER_03: we're very fortunate to have a universal health system where people don't have
- 0:21SPEAKER_03: to worry about costs and drug access and availability.
- 0:25SPEAKER_03: And so I think that's why it was such a shock for women to realize
- 0:30SPEAKER_03: that actually this lifesaving medicine may no longer be available come November
- 0:35SPEAKER_03: 2026.
- 0:44SPEAKER_00: Thanks everyone for joining us for another episode of The Meaning of Health.
- 0:48SPEAKER_00: We've got two great guests with us today to talk about a very current issue
- 0:51SPEAKER_00: which people may have read about and seen in the media.
- 0:57SPEAKER_00: So it gives me great pleasure to welcome Dr.
- 1:01SPEAKER_00: Monica Tang and Professor Sally Pearson to the podcast.
- 1:06SPEAKER_00: Monica and Sally,
- 1:06SPEAKER_00: are you happy to give listeners a bit of an introduction about yourselves and
- 1:11SPEAKER_00: the work that you do?
- 1:15SPEAKER_03: Yeah, sure.
- 1:15SPEAKER_03: Thanks so much for having us on the podcast, Craig.
- 1:19SPEAKER_03: It's great to be back.
- 1:21SPEAKER_03: So I am a medical oncologist working in Sydney at Prince of Wales Hospital.
- 1:28SPEAKER_03: I specialise in the treatment of breast cancer and I also lead
- 1:33SPEAKER_03: the Cancer Survivorship Service at Prince of Wales.
- 1:37SPEAKER_00: Yeah.
- 1:39SPEAKER_02: Hi, everyone.
- 1:41SPEAKER_02: Craig, thanks for the invitation.
- 1:43SPEAKER_02: I am a health systems researcher and pharmacoepidemiologist.
- 1:49SPEAKER_02: I'm based at UNSW.
- 1:52SPEAKER_02: And I'm really passionate about doing research that's focused on the youth safety,
- 1:58SPEAKER_02: effectiveness and equitable access of medicines in Australia and beyond.
- 2:04SPEAKER_02: And I've been working for more than a couple of decades now.
- 2:10SPEAKER_02: On research around how pharmaceutical policy decisions affect patient
- 2:17SPEAKER_02: and health system
- 2:18SPEAKER_01: outcomes.
- 2:18SPEAKER_01: So this conversation today is right up my alley, Craig.
- 2:23SPEAKER_01: So I really appreciate the invitation.
- 2:26SPEAKER_00: Great.
- 2:26SPEAKER_00: It's great that you could both join us.
- 2:28SPEAKER_00: I know everyone's busy at the moment and issues like the ones that we're going
- 2:32SPEAKER_00: to talk about today are obviously keeping us busy.
- 2:34SPEAKER_00: So what I'm talking about is the recent Zoladex withdrawal from the market
- 2:39SPEAKER_00: in Australia and then And there was a lot of coverage about this,
- 2:45SPEAKER_00: not least because it's a really important drug for people who are being treated
- 2:49SPEAKER_00: for cancer.
- 2:51SPEAKER_00: But Monica,
- 2:51SPEAKER_00: did you want to give us a bit of a background as to what happened and why
- 2:55SPEAKER_00: that matters?
- 2:57SPEAKER_03: Yes.
- 2:58SPEAKER_03: So Zolodix is the brand name for Gozerulin, which is the generic name.
- 3:05SPEAKER_03: It belongs to a class of drugs called Zolodix.
- 3:08SPEAKER_03: I use it commonly when I look after pre-menopausal women with breast cancer,
- 3:11SPEAKER_03: but it's actually used for fertility preservation
- 3:12SPEAKER_03: for women undergoing cancer treatment for all types of cancer.
- 3:32SPEAKER_03: What happened was earlier this year,
- 3:33SPEAKER_03: I think at about April or May,
- 3:36SPEAKER_03: AstraZeneca,
- 3:37SPEAKER_03: who are the manufacturers of Zolidex,
- 3:40SPEAKER_03: announced that they would be withdrawing this product from the public market
- 3:44SPEAKER_03: in Australia so that it would no longer be available.
- 3:46SPEAKER_03: Yeah, thanks for that background.
- 4:11SPEAKER_00: Yeah,
- 4:11SPEAKER_00: so basically there was that announcement and people were quite rightly panicked
- 4:16SPEAKER_00: about the consequences of this.
- 4:19SPEAKER_00: Now, is one of the reasons for that because there's not a lot of alternatives out there?
- 4:25SPEAKER_03: Yeah, absolutely.
- 4:27SPEAKER_03: I think that there has been some equity and gender equity issues prior
- 4:33SPEAKER_03: to this announcement, but it wasn't made very obvious until...
- 4:36SPEAKER_03: AstraZeneca made their announcement.
- 4:40SPEAKER_03: So as I mentioned, Zolidex is one of a class of drugs called GnRH agonists.
- 4:45SPEAKER_03: Now it turns out that in Australia,
- 4:48SPEAKER_03: only Zolidex was PBS listed and available for women to treat premenopausal
- 4:54SPEAKER_03: with women with breast cancer as part of fertility treatment like IVF,
- 4:59SPEAKER_03: also for fertility preservation for women undergoing cancer treatment for all types
- 5:04SPEAKER_03: of cancers.
- 5:06SPEAKER_03: However,
- 5:08SPEAKER_03: JNRH agonists can also be used to treat prostate cancer,
- 5:12SPEAKER_03: prostate cancer also being a hormone sensitive cancer that responds
- 5:16SPEAKER_03: to hormonal manipulation.
- 5:18SPEAKER_03: And there are actually three other alternative medications on the PBS to treat men
- 5:23SPEAKER_03: with prostate cancer.
- 5:25SPEAKER_03: And so when AstraZeneca made this decision to withdraw Zolidex,
- 5:29SPEAKER_03: what it meant was that men would still have alternative medicines,
- 5:33SPEAKER_03: so two to three other medicines that their oncologist could provide and prescribe
- 5:37SPEAKER_03: to them for ongoing treatment.
- 5:39SPEAKER_03: However,
- 5:40SPEAKER_03: for women,
- 5:40SPEAKER_03: there were no other options on the PBS,
- 5:42SPEAKER_03: and that's why this created such a difficult situation.
- 5:49SPEAKER_02: And I think, Craig, one of the things that it's...
- 5:56SPEAKER_02: Patients who are undergoing treatment are appropriately nervous and anxious
- 6:03SPEAKER_02: about making sure they get the best absolute care possible in the course
- 6:08SPEAKER_02: of their treatment.
- 6:11SPEAKER_02: And the fact that something was going to be withdrawn and taken away rightly created
- 6:16SPEAKER_02: a lot of anxiety, concerns about what their outcomes might play out, etc.
- 6:29SPEAKER_02: That would happen across the board, regardless of the gender issues.
- 6:32SPEAKER_01: But Monica's beautifully highlighted that there were specific issues around this one
- 6:38SPEAKER_01: that seem to have a gender equity lens as well.
- 6:43SPEAKER_03: Yeah, and you're right, Sal.
- 6:44SPEAKER_03: I think the anxiety around drug availability and being able to receive really,
- 6:50SPEAKER_03: you know,
- 6:51SPEAKER_03: standard of care,
- 6:52SPEAKER_03: world class treatment is always at the forefront of people's minds.
- 6:55SPEAKER_03: I think in Australia,
- 6:56SPEAKER_03: we're very fortunate to have a universal health system where,
- 7:00SPEAKER_03: you know, people don't have to worry about costs and drug access and availability.
- 7:05SPEAKER_03: And so I think that's why it was...
- 7:07SPEAKER_03: Such a shock for women to realise
- 7:10SPEAKER_03: that actually this life-saving medicine may no longer be available come November
- 7:15SPEAKER_03: 2026.
- 7:17SPEAKER_03: I see dozens of women in my breast cancer clinics every week and
- 7:22SPEAKER_03: And I was facing this at the cold face that people were asking, what will I do?
- 7:27SPEAKER_03: What does this mean for my cancer?
- 7:29SPEAKER_03: And how will I, you know, prevent the cancer from coming back?
- 7:32SPEAKER_03: How can I stop this cancer from spreading and causing early death?
- 7:36SPEAKER_03: And that was really distressing for myself,
- 7:38SPEAKER_03: for my colleagues,
- 7:39SPEAKER_03: for the nurses and other oncologists,
- 7:41SPEAKER_03: and, you know, least of all, the patients and their families.
- 7:45SPEAKER_00: Yeah, absolutely.
- 7:46SPEAKER_00: Yeah, I could imagine that that would have stretched the skill set
- 7:51SPEAKER_00: that you've been trained in,
- 7:52SPEAKER_00: you know,
- 7:53SPEAKER_00: you're trained to treat people for cancer and then you're having to be a counsellor
- 7:57SPEAKER_00: at the same time and yeah, that'd be quite difficult.
- 8:01SPEAKER_00: Now, before we start talking about,
- 8:03SPEAKER_00: you know,
- 8:03SPEAKER_00: the AstraZeneca side of this and why they may have made the decisions,
- 8:07SPEAKER_00: I'm curious to know whether there's a gender equity issue more broadly
- 8:11SPEAKER_00: in cancer medications, but sort of in medications generally.
- 8:14SPEAKER_00: I know around sort of,
- 8:17SPEAKER_00: you know,
- 8:17SPEAKER_00: a good example around menopause,
- 8:18SPEAKER_00: hormone replacement therapy,
- 8:20SPEAKER_00: you know, that's been an issue that's been discussed, you know, more recently.
- 8:25SPEAKER_00: But yeah,
- 8:25SPEAKER_00: in cancer treatment,
- 8:26SPEAKER_00: are there gender equity issues with regards to sort of medicines that are available?
- 8:31SPEAKER_03: You know what?
- 8:33SPEAKER_03: I actually think generally not.
- 8:36SPEAKER_03: I guess I come from a slightly biased perspective in
- 8:39SPEAKER_03: that I solely treat breast cancer and the vast majority of my patients are women.
- 8:45SPEAKER_03: I have to say that women with breast cancer are actually really effective advocates
- 8:51SPEAKER_03: for the sorts of treatments that they need and,
- 8:54SPEAKER_03: you know, the things that they would like to access.
- 8:56SPEAKER_03: And I think generally speaking compared to a lot of cancers,
- 9:00SPEAKER_03: you know,
- 9:01SPEAKER_03: Patients with breast cancers do actually have quite good access to medicines.
- 9:08SPEAKER_03: I think this is a situation that has obviously been happening for many decades,
- 9:13SPEAKER_03: the fact that there's been a disparity between access to exactly the same type
- 9:17SPEAKER_03: of medicine and the recent decision from AstraZeneca has just really shone
- 9:23SPEAKER_03: a spotlight on it.
- 9:26SPEAKER_00: Yes, Sally.
- 9:28SPEAKER_02: So at a bigger picture level,
- 9:31SPEAKER_02: not specific to cancer,
- 9:33SPEAKER_02: one of the things that is very interesting in terms of that brings
- 9:37SPEAKER_02: the gender differences in is a lot of clinical trials,
- 9:42SPEAKER_02: for example, have mostly male participants.
- 9:47SPEAKER_02: So a lot of the evidence that's generated is For in guidelines and the evidence
- 9:55SPEAKER_02: that underpins a listing decision to go on the PBS.
- 9:59SPEAKER_02: There are some disparities in what the participants of the trials look like and
- 10:04SPEAKER_02: then we make these experiments.
- 10:06SPEAKER_02: Extrapolations that the benefits derived in the trial populations are going
- 10:11SPEAKER_02: to be benefits that we see in real world practice.
- 10:14SPEAKER_02: But when you start unpicking that,
- 10:17SPEAKER_02: is it reasonable to expect that a trial that is predominantly men is going
- 10:22SPEAKER_02: to translate into best outcomes for women, et cetera?
- 10:27SPEAKER_02: Same thing goes for age and other things, but it kind of is...
- 10:33SPEAKER_02: Apparent way further down in the pipeline, at the beginnings of that pipeline.
- 10:39SPEAKER_02: And I'm delighted to say that there's a lot of dialogue around redressing that at
- 10:45SPEAKER_02: the moment in clinical trial designers.
- 10:48SPEAKER_02: But I think it does actually raise issues,
- 10:52SPEAKER_02: not just in the drug availability
- 10:55SPEAKER_01: space in the PBS,
- 10:56SPEAKER_01: but what's happening further downstream that also potentially creates
- 11:04SPEAKER_01: a greater divide as you get more upstream in that pipeline, if that makes sense.
- 11:10SPEAKER_03: Yeah.
- 11:11SPEAKER_03: And you're right, Sal.
- 11:12SPEAKER_03: It's not just,
- 11:13SPEAKER_03: you know,
- 11:13SPEAKER_03: under-representation of women,
- 11:14SPEAKER_03: you know,
- 11:15SPEAKER_03: older patients,
- 11:16SPEAKER_03: patients with poor performance status or comorbidities,
- 11:18SPEAKER_03: but the fact that younger women of childbearing age and certainly women
- 11:23SPEAKER_03: who are pregnant are almost uniformly excluded from the major trials
- 11:28SPEAKER_03: that PBAC makes decisions about whether or not to list a drug in.
- 11:32SPEAKER_03: If medication becomes available,
- 11:35SPEAKER_03: then we're left with this absence of data around safety and efficacy
- 11:39SPEAKER_03: in those excluded populations.
- 11:42SPEAKER_03: And I think it would probably be very difficult to conduct clinical trials
- 11:46SPEAKER_03: of novel medicines in.
- 11:47SPEAKER_03: Pregnant women, there's good reason for them to be excluded.
- 11:50SPEAKER_03: And, you know,
- 11:51SPEAKER_03: women of childbearing age because of the uncertainty around the impacts
- 11:55SPEAKER_03: on fertility.
- 11:55SPEAKER_03: But I think that's where,
- 11:57SPEAKER_03: you know,
- 11:57SPEAKER_03: down the track real world data about how these medicines are used and what
- 12:01SPEAKER_03: the potential implications are.
- 12:03SPEAKER_03: They're really important to inform clinical practice.
- 12:07SPEAKER_00: Yeah.
- 12:07SPEAKER_00: Well,
- 12:08SPEAKER_00: I think we're fortunate to have colleagues in our Centre for Medicines Intelligence
- 12:14SPEAKER_00: that are looking at medication safety in pregnancy.
- 12:17SPEAKER_00: Absolutely.
- 12:19SPEAKER_00: I sit on an ethics committee that has a look at a lot of ethics applications.
- 12:22SPEAKER_00: Yeah.
- 12:38SPEAKER_01: I think there's some really important policy movement in this space and
- 12:45SPEAKER_01: the awareness has certainly been raised.
- 12:47SPEAKER_01: So I'm feeling far more optimistic about how this is going to play out down the track.
- 12:55SPEAKER_01: So the movement is in the right direction.
- 12:59SPEAKER_00: Yeah, that's good.
- 13:00SPEAKER_00: It's good to have people advocating as well because I think that maybe was a bit of
- 13:04SPEAKER_00: a missing piece or maybe not missing but an unheard piece.
- 13:09SPEAKER_00: People maybe weren't paying as much attention
- 13:11SPEAKER_00: because I'm sure people have been advocating for a long time.
- 13:15SPEAKER_00: Yeah, so I'm curious to sort of,
- 13:17SPEAKER_00: I guess,
- 13:18SPEAKER_00: if you can get into the minds of AstraZeneca as
- 13:21SPEAKER_00: to why they would do something like this, you know, for such an important drug.
- 13:24SPEAKER_00: I mean, in the medical profession, is there a view as to why this happened?
- 13:31SPEAKER_03: Look, it's difficult.
- 13:33SPEAKER_03: I've been thinking about this question for a number of months.
- 13:35SPEAKER_03: I think the official...
- 13:37SPEAKER_03: Party line is that it was made for commercial interests,
- 13:41SPEAKER_03: but the miniature of those commercial interests have not become transparent.
- 13:48SPEAKER_03: I think the belief is that AstraZeneca felt that the price that
- 13:52SPEAKER_03: the Australian government was paying for Zolodex was too low,
- 13:57SPEAKER_03: and that would affect their negotiations with other jurisdictions
- 14:02SPEAKER_03: and other countries overseas if they saw the Australian price change.
- 14:05SPEAKER_03: As a potential benchmark to judge against,
- 14:09SPEAKER_03: I believe,
- 14:10SPEAKER_03: the Australian market for Zolidex is relatively small,
- 14:12SPEAKER_03: only about 2% of the global market.
- 14:14SPEAKER_03: And so they felt that they were probably happy to forego that 2% if they were able
- 14:20SPEAKER_03: to be in a more Advantageous position in terms of negotiating
- 14:25SPEAKER_03: with other health systems overseas.
- 14:28SPEAKER_03: I don't know, Sarah, if you have any insights.
- 14:30SPEAKER_02: Yeah, look,
- 14:32SPEAKER_02: I really don't want to get into too much speculation as to what underpinned that
- 14:37SPEAKER_02: That decision and your reflections, Monica,
- 14:43SPEAKER_02: seem to really
- 14:45SPEAKER_01: align with the discussions that I've had
- 14:48SPEAKER_01: with various people around this,
- 14:50SPEAKER_01: but I think it also throws up a really interesting issue from a policy perspective,
- 14:56SPEAKER_01: particularly in a market like ours in Australia, which is very small globally.
- 15:01SPEAKER_01: What safeguards actually exist for us
- 15:04SPEAKER_01: when commercially driven decisions like this really affect Clinical access
- 15:12SPEAKER_01: for people.
- 15:13SPEAKER_01: And I'm certainly not suggesting that we try and address
- 15:16SPEAKER_01: that big picture issue today,
- 15:18SPEAKER_01: but it's really started a lot
- 15:21SPEAKER_01: of thinking appropriately around what safeguards we can actually put in place to try
- 15:27SPEAKER_01: and protect our community and provide the best possible care that we can.
- 15:32SPEAKER_00: Yeah.
- 15:34SPEAKER_00: It kind of touches on an interesting area around the ethics of pharmaceuticals.
- 15:40SPEAKER_00: Obviously, they're not a publicly owned, they're not a government owned entity, AstraZeneca.
- 15:45SPEAKER_00: They're a private firm.
- 15:47SPEAKER_00: So, they really have the right to pick and choose what they choose to do, right?
- 15:51SPEAKER_00: Absolutely.
- 15:53SPEAKER_00: I mean, it seems like withdrawing their drug was one of the options.
- 15:59SPEAKER_00: Another option would have possibly been to renegotiate and sort of say to
- 16:04SPEAKER_00: the government,
- 16:04SPEAKER_00: well, you know, it's not commercially viable for us at the current price.
- 16:11SPEAKER_00: So we're thinking of withdrawing it.
- 16:13SPEAKER_00: But if you were to raise that price point, then perhaps we could reconsider.
- 16:17SPEAKER_00: But I don't know what goes into those conversations.
- 16:20SPEAKER_00: I don't know either of you would have been privy to any of that.
- 16:24SPEAKER_02: Even if we were, we couldn't talk about it.
- 16:30SPEAKER_01: So look, that kind of conversation could well have happened, Craig.
- 16:35SPEAKER_01: And I mean,
- 16:37SPEAKER_01: it's not, again,
- 16:38SPEAKER_01: for us to speculate what's happened behind closed doors,
- 16:42SPEAKER_01: because as you know,
- 16:44SPEAKER_01: all of these negotiations are commercial in confidence and not publicly available.
- 16:50SPEAKER_01: But again, just kind of spinning this around, I think the important thing from,
- 16:59SPEAKER_01: And we don't have any control over what a commercial entity decides to do.
- 17:05SPEAKER_01: That's very clear in this context.
- 17:07SPEAKER_01: But spinning around and starting to think about the policy challenge, which is how do we...
- 17:13SPEAKER_01: We as a nation and as a program like the PBS protect patients from
- 17:19SPEAKER_01: the unintended consequences of withdrawals like this.
- 17:23SPEAKER_01: I think that's something we've got probably far more control over.
- 17:28SPEAKER_01: And appropriate levers to support that than we have trying
- 17:32SPEAKER_01: to predict what companies are going to do.
- 17:37SPEAKER_01: Craig, I'm certainly not dismissing it,
- 17:39SPEAKER_01: but I think it's something that certainly from where Monica
- 17:42SPEAKER_01: and I sit have no control over whatsoever.
- 17:45SPEAKER_01: So thinking about where we can support the alternative,
- 17:49SPEAKER_01: which is protecting patients is I think where we probably can make some gains.
- 18:15SPEAKER_00: For people listening who may not be overly familiar with how our medications kind
- 18:19SPEAKER_00: of regulation and supply works.
- 18:22SPEAKER_00: So there's a lot of discussion at the moment about the fact that the PBS is
- 18:27SPEAKER_00: a really powerful negotiator in drug purchasing.
- 18:32SPEAKER_00: Why does the PBS have so much power or the people behind the PBS compared
- 18:37SPEAKER_00: to other countries maybe where drugs get sold at a higher price?
- 18:41SPEAKER_00: How do we end up in the position that we're in?
- 18:44SPEAKER_01: This is a whole separate podcast, you know, Craig.
- 18:48SPEAKER_02: But look,
- 18:50SPEAKER_02: in very simple terms,
- 18:52SPEAKER_02: because the PBS basically is a monopoly in a sense that it's
- 19:00SPEAKER_01: got a lot
- 19:00SPEAKER_01: of purchasing power because it's...
- 19:02SPEAKER_01: It provides access to medicines for the entire country.
- 19:06SPEAKER_01: It's not like the US,
- 19:08SPEAKER_01: for example,
- 19:09SPEAKER_01: where there's dozens and dozens of different schemes,
- 19:13SPEAKER_01: Medicare, Medicaid, private health insurers, and so on.
- 19:17SPEAKER_01: So the companies are actually physically negotiating with the monopoly to supply those.
- 19:26SPEAKER_01: Obviously drugs can be accessed in other ways,
- 19:28SPEAKER_01: but the power,
- 19:30SPEAKER_01: and I say that is in inverted commas,
- 19:33SPEAKER_01: is that it is the sole place,
- 19:40SPEAKER_01: the sole front door that companies are negotiating with.
- 19:43SPEAKER_01: That's very simple terms.
- 19:47SPEAKER_01: But I think that's the crux of it.
- 19:50SPEAKER_00: Yeah.
- 19:50SPEAKER_00: Monica?
- 19:52SPEAKER_03: I think while we're on the topic of,
- 19:54SPEAKER_03: you know,
- 19:54SPEAKER_03: the role of the government and,
- 19:55SPEAKER_03: you know,
- 19:56SPEAKER_03: obviously the advantages of having the PBS is the one sort of negotiating power.
- 20:01SPEAKER_03: The situation's also made me think about,
- 20:04SPEAKER_03: you know,
- 20:04SPEAKER_03: the responsibility of the government to ensure access to medicines,
- 20:08SPEAKER_03: as Sal mentioned earlier.
- 20:10SPEAKER_03: The World Health Organization,
- 20:13SPEAKER_03: the WHO,
- 20:14SPEAKER_03: actually publishes a list of essential medicines,
- 20:17SPEAKER_03: which they have identified as medicines that everyone should have access to all
- 20:23SPEAKER_03: the time,
- 20:24SPEAKER_03: and that all governments should ensure are available and affordable
- 20:27SPEAKER_03: to their populations.
- 20:28SPEAKER_03: And so this list is actually carefully curated.
- 20:31SPEAKER_03: It doesn't include a lot of Novel high-cost medicines
- 20:34SPEAKER_03: because I think it's not reasonable to expect all or most governments to be able
- 20:39SPEAKER_03: to provide access to the newest cancer medicine that was just released last month.
- 20:46SPEAKER_03: And so GNIH agonists like Zolidex are actually on that list of medicines.
- 20:53SPEAKER_03: It seems like the decision to A,
- 20:56SPEAKER_03: make medicines available on the PBS through applications to the PBAC,
- 21:00SPEAKER_03: but also to withdraw medicines such as the case from Zolodex is very much driven
- 21:05SPEAKER_03: by commercial interests and they're led by the manufacturers.
- 21:10SPEAKER_03: And so in this situation,
- 21:12SPEAKER_03: it felt to me that the government,
- 21:14SPEAKER_03: although I thought that they had in principle a responsibility to provide access,
- 21:18SPEAKER_03: they decided I don't know,
- 21:20SPEAKER_03: they potentially were a little bit on the back foot or they weren't able
- 21:24SPEAKER_03: to initiate all the things that needed to happen from my perspective
- 21:28SPEAKER_03: without knowing all things and outs.
- 21:30SPEAKER_00: Thanks, Monica.
- 21:32SPEAKER_02: So Monica brings up some interesting points.
- 21:35SPEAKER_02: And the other thing that is important to understand about the PBS is
- 21:42SPEAKER_02: that Andrew Wilson,
- 21:44SPEAKER_02: who was the chair of the PBS for many years,
- 21:47SPEAKER_02: around a decade, to use his terminology, the PBS is a reactive system.
- 21:55SPEAKER_02: And what that means is that the PBS doesn't go out searching...
- 22:01SPEAKER_02: Four medicines to fill treatment gaps.
- 22:05SPEAKER_02: In fact,
- 22:06SPEAKER_02: it actually requires a sponsor who's the pharmaceutical industry most commonly
- 22:11SPEAKER_02: to put in an application for listing.
- 22:15SPEAKER_02: So there's been a recent review of the PBS in that context and there is a view now
- 22:24SPEAKER_02: and some recommendations that there should be some horizon scanning
- 22:28SPEAKER_02: that means it will become more I think that's a really important thing
- 22:33SPEAKER_02: that people need to understand.
- 22:50SPEAKER_00: So more a case of assessing sort of pressing need in the community and saying,
- 22:55SPEAKER_00: right,
- 22:55SPEAKER_00: these are the companies that could actually address that need rather than saying,
- 22:58SPEAKER_00: waiting for those companies to say, we want to sell out.
- 23:01SPEAKER_00: To come to the PBS.
- 23:03SPEAKER_02: And there's other systems in the world that obviously have a more proactive system doing that.
- 23:09SPEAKER_02: And I think there's a lot of thought being put into how that
- 23:14SPEAKER_01: may occur.
- 23:15SPEAKER_01: So there's a beautiful I'm curious as to whether there's an example or two
- 23:19SPEAKER_01: of countries who are more proactive in this space.
- 23:46SPEAKER_02: Yeah, look, I think Canada is the example that has been used in the past.
- 23:53SPEAKER_02: I think New Zealand do that as well, Craig.
- 23:58SPEAKER_02: Please don't quote me on that because this is just totally off the top of my head.
- 24:02SPEAKER_02: But also keep in mind Canada's
- 24:04SPEAKER_01: drug benefits are provincial.
- 24:06SPEAKER_01: They're not whole country.
- 24:08SPEAKER_01: So there's probably quite a bit of variation there.
- 24:11SPEAKER_01: But yeah, Yeah,
- 24:14SPEAKER_01: there's many examples globally where there's a much more front foot approach
- 24:20SPEAKER_01: to seeking out drugs that would benefit from public subsidy.
- 24:26SPEAKER_00: I'm just thinking on the run a little bit about something you mentioned
- 24:29SPEAKER_00: about there being a safeguard against something like this,
- 24:32SPEAKER_00: what's happened with Zolodex happening in future.
- 24:35SPEAKER_00: What sort of ideas would there be out there that we could explore for safeguards?
- 24:41SPEAKER_01: Monica, do you want to have a massive question?
- 24:45SPEAKER_03: Yeah, look,
- 24:46SPEAKER_03: it's definitely sort of outside my area of expertise,
- 24:49SPEAKER_03: but I think I was speaking with a colleague about sometimes the PBAC,
- 24:54SPEAKER_03: if there are situations where there's an anticipated shortage of a medicine
- 24:58SPEAKER_03: that they could...
- 25:00SPEAKER_03: You know, try to reach out to see what alternative medicines are available.
- 25:05SPEAKER_03: And I think that's a great safeguard to anticipate potential shortfalls.
- 25:10SPEAKER_03: I think in this situation,
- 25:11SPEAKER_03: it wasn't a matter of a shortage,
- 25:13SPEAKER_03: but I think this is a situation where it would have been great if there was
- 25:17SPEAKER_03: an avenue for the PBAC and the Department of Health
- 25:20SPEAKER_03: to seek out alternatives once this news became available.
- 25:25SPEAKER_03: I don't know how hard that would be to legislate or to put into practice, though.
- 25:31SPEAKER_02: So in a lot of ways, I think Monica's brought up something really important.
- 25:35SPEAKER_02: You know,
- 25:35SPEAKER_02: shortages are something that
- 25:39SPEAKER_01: the government are constantly trying to manage
- 25:42SPEAKER_01: and they do a pretty good job at trying to predict and model.
- 25:46SPEAKER_01: And this is an extreme shortage if you want to think about it in another way.
- 25:51SPEAKER_01: And bringing it more back to what we have an expertise in
- 25:56SPEAKER_01: because you're certainly encroaching into territory that,
- 26:00SPEAKER_01: you know, I don't feel particularly comfortable talking about with authority.
- 26:05SPEAKER_01: But one of the things, Craig,
- 26:07SPEAKER_01: where we have amazing capacity now is with the data that we hold
- 26:14SPEAKER_01: in this country that's generated through the PBS and otherwise.
- 26:17SPEAKER_01: So there's a capacity
- 26:19SPEAKER_01: if something like this is anticipated whereby Data can be analysed,
- 26:25SPEAKER_01: you can start to understand the numbers of people affected,
- 26:28SPEAKER_01: where they live,
- 26:30SPEAKER_01: what their characteristics are and what potentially,
- 26:33SPEAKER_01: so you can at least start quantifying the enormity of the problem and
- 26:37SPEAKER_01: then start thinking about various policy levers and other things you might want
- 26:44SPEAKER_01: to put in place to help, I guess, deal with those unintended consequences.
- 26:51SPEAKER_00: Yeah, so why don't we go there, Sal,
- 26:53SPEAKER_00: because that is your area of expertise is data and, you know, pharmacoepidemiology.
- 27:00SPEAKER_00: What can we learn about,
- 27:02SPEAKER_00: from this example,
- 27:03SPEAKER_00: about the importance of data to help drive some of these decisions?
- 27:07SPEAKER_00: Yeah.
- 27:08SPEAKER_02: Yeah, so we're very proud of this little example that we're going to give
- 27:13SPEAKER_02: and I think I'll throw to Monica first to give a quick bit of background
- 27:17SPEAKER_02: about what we did in the data space to actually help support,
- 27:24SPEAKER_01: generate some evidence that was quite useful in the context
- 27:28SPEAKER_01: of PBAC deciding what they needed to do in response to this.
- 27:32SPEAKER_01: So Monica,
- 27:33SPEAKER_01: why don't you give a little bit of background and then I can talk about
- 27:36SPEAKER_01: the data side of things.
- 27:39SPEAKER_03: Yes.
- 27:39SPEAKER_03: So as you know, Craig,
- 27:40SPEAKER_03: I was very excited when you emailed me a few weeks ago about this topic
- 27:45SPEAKER_03: because it's something very close to my heart and something I've been working on
- 27:48SPEAKER_03: with Sal and her team for a couple of months.
- 27:51SPEAKER_03: So as I mentioned, I was really seeing the candidates.
- 27:54SPEAKER_03: And at the same time,
- 28:01SPEAKER_03: I guess I'm also fortunate enough to have a bit of research experience
- 28:06SPEAKER_03: in real-world diet research.
- 28:07SPEAKER_03: I actually did my PhD under sales supervision a few years ago.
- 28:13SPEAKER_03: So she's great.
- 28:16SPEAKER_00: Goes with that saying.
- 28:17SPEAKER_03: Yeah, very, very good.
- 28:21SPEAKER_03: And I'm very lucky to still be working with her team.
- 28:24SPEAKER_03: And so I thought,
- 28:26SPEAKER_03: given that there was a lot of media attention about the potential impacts of
- 28:30SPEAKER_03: the withdrawal of Zolidex,
- 28:32SPEAKER_03: it would be great to actually have some hard numbers and facts to really try
- 28:37SPEAKER_03: and describe the extent of the impact in terms
- 28:41SPEAKER_03: of how many people are using Zolidex currently,
- 28:45SPEAKER_03: what the trends are in terms of You know,
- 28:49SPEAKER_03: how many people are likely to be affected in coming years
- 28:52SPEAKER_03: if Zolidex was no longer available.
- 28:54SPEAKER_03: And so I approached Sal and also Ben Daniels, who's a pharmacoepidemiologist on Sal's team.
- 29:02SPEAKER_03: And so we decided to put together a project describing sort of trends in health.
- 29:09SPEAKER_03: The use of Zolidex over the last 10 years and also currently just to give
- 29:13SPEAKER_03: a real up-to-date snapshot of how many women will be affected by this decision
- 29:17SPEAKER_03: and obviously that's been made available by a lot of groundwork that sales played
- 29:22SPEAKER_03: over the past years and maybe decades.
- 29:26SPEAKER_02: Now she's telling you that I've been around a long time.
- 29:31SPEAKER_02: So thanks for the background.
- 29:34SPEAKER_02: So this is a really great example of the kinds of things that,
- 29:39SPEAKER_02: you know,
- 29:41SPEAKER_02: myself and a number of contemporaries have been pushing for for a long time, Craig,
- 29:47SPEAKER_02: which is to have Available data available to be able to respond quickly
- 29:55SPEAKER_02: to these kinds of needs.
- 29:57SPEAKER_02: So interestingly enough,
- 29:58SPEAKER_02: when Monica first came to us with this idea,
- 30:03SPEAKER_02: it was really in the context of of an advocacy piece to publish something in
- 30:09SPEAKER_02: a medical journal where we could go,
- 30:12SPEAKER_02: hey guys, this is potentially going to be a big problem.
- 30:15SPEAKER_02: So it was awareness raising.
- 30:17SPEAKER_02: We'd also thought about some lay summaries that we could get out.
- 30:22SPEAKER_02: So people were really acutely aware of what the consequences were,
- 30:27SPEAKER_02: but also should put some hard numbers around this.
- 30:30SPEAKER_02: Coincidentally,
- 30:32SPEAKER_02: through the Medicines Intelligence CRE,
- 30:35SPEAKER_02: we have regular discussions with people from government around the kinds
- 30:40SPEAKER_02: of work we're doing and how we can provide timely evidence to them to inform some of
- 30:47SPEAKER_02: the work they're doing.
- 30:49SPEAKER_02: At a recent meeting,
- 30:50SPEAKER_02: we just mentioned that we were doing this work on Zolidex and they said,
- 30:54SPEAKER_02: oh my goodness,
- 30:57SPEAKER_02: We really would love those hard numbers to try and there's a special meeting
- 31:04SPEAKER_02: where they could be very useful.
- 31:06SPEAKER_02: So because of the approvals that we already have in place to access these data,
- 31:13SPEAKER_02: so that's ethical approval and appropriate governance approval,
- 31:17SPEAKER_02: we were at the ready where we could turn these data around very quickly.
- 31:22SPEAKER_02: So we accessed these data in highly secure environments.
- 31:27SPEAKER_02: People's names and specific details are not available to us.
- 31:33SPEAKER_01: It's population level,
- 31:35SPEAKER_01: but we were able to very quickly turn this around and provide it in a timely way for
- 31:41SPEAKER_01: the PBAC to have a really informed decision around the numbers that that's affected
- 31:48SPEAKER_01: and then their subsequent decisions.
- 31:51SPEAKER_01: We now have capacity to do this quickly Craig it's a great example
- 31:56SPEAKER_01: of our national capability and we're really keen through the CRE as you know
- 32:03SPEAKER_01: to really uplift this and scale it up so we're not just doing one-off examples
- 32:08SPEAKER_01: but we can do this regularly to ultimately benefit the Australian community.
- 32:16SPEAKER_00: Yeah.
- 32:16SPEAKER_00: And so was it just serendipity for this particular drug that you happened
- 32:19SPEAKER_00: to have had an interest in it and it aligned with the timing of this issue
- 32:23SPEAKER_00: of emerging?
- 32:25SPEAKER_02: It was serendipitous and not surprisingly because across a lot of
- 32:32SPEAKER_01: the drug policy issues,
- 32:34SPEAKER_01: we're often doing research that aligns very closely
- 32:38SPEAKER_01: with what government are interested in.
- 32:40SPEAKER_01: But again, you highlight a really
- 32:43SPEAKER_02: important issue.
- 32:45SPEAKER_02: For us to have a mature data system that gives that rapid
- 32:49SPEAKER_01: response Then it needs
- 32:52SPEAKER_01: to move from serendipity into something that's more structured and comprehensive so
- 32:58SPEAKER_01: that questions can be fed around the country to people who have access
- 33:03SPEAKER_01: to these data.
- 33:04SPEAKER_01: So we can flip it around quickly because the government,
- 33:08SPEAKER_01: there's some great expertise within government, but their resources are limited.
- 33:13SPEAKER_01: So what we're trying to do is join forces so that as a community,
- 33:18SPEAKER_01: Data analysts,
- 33:20SPEAKER_01: data scientists,
- 33:21SPEAKER_01: we can all start building this evidence base in a really timely way
- 33:27SPEAKER_01: to inform policy.
- 33:29SPEAKER_00: And were the people involved in those kind of high level discussions that said
- 33:34SPEAKER_00: to you we could really do with those data,
- 33:35SPEAKER_00: were they aware of your capability to do this prior to that?
- 33:39SPEAKER_02: Yeah, so the CRE has set up regular meetings with people from
- 33:48SPEAKER_02: the Pharmaceutical Benefits Advisory Committee, the Secretariat of those committees.
- 33:54SPEAKER_02: We meet probably between every month to two months and so we're constantly feeding
- 34:01SPEAKER_02: in what's going on and we're providing early results of the work that we're going
- 34:07SPEAKER_02: to have published.
- 34:09SPEAKER_02: We've come a long way in the last five years since the CRE has been funded,
- 34:12SPEAKER_02: but Craig, I'm really passionate about
- 34:29SPEAKER_01: Really scaling it up so that it's not reliant on serendipity,
- 34:34SPEAKER_01: but rather clear processes where these questions can be fed in
- 34:39SPEAKER_01: and we can respond more quickly to them.
- 35:01SPEAKER_00: Yeah, it sounds like there's definitely scope for us as a nation to do some kind
- 35:06SPEAKER_00: of risk analysis of drugs like this.
- 35:10SPEAKER_00: Absolutely.
- 35:11SPEAKER_00: And I'm sure there's many out there that are sort of life-preserving or extending
- 35:14SPEAKER_00: or life-saving drugs.
- 35:16SPEAKER_02: So Craig,
- 35:17SPEAKER_02: I do want to clarify that there's people within government
- 35:20SPEAKER_02: that are also doing this work,
- 35:22SPEAKER_02: but I think that where we added value is the analysis was quite complex in
- 35:31SPEAKER_02: that we had to delineate between people with cancer and other indications.
- 35:37SPEAKER_02: And because of Monica's clinical expertise and work we'd previously done,
- 35:43SPEAKER_02: we could actually We had a big number,
- 35:49SPEAKER_02: but what proportion of that were women who were getting this drug for
- 35:54SPEAKER_02: the indication we're talking about?
- 35:56SPEAKER_02: And that's the value
- 35:58SPEAKER_01: we could add.
- 35:59SPEAKER_01: Whereas I think the government analysis was likely to just be that broad number.
- 36:04SPEAKER_01: We were able to do some deep dives because of the planets aligned in terms
- 36:10SPEAKER_01: of our expertise and what we were doing at the time.
- 36:13SPEAKER_00: Yeah, highlighting the multidisciplinary approach and the value of that, right?
- 36:19SPEAKER_00: Absolutely.
- 36:20SPEAKER_00: So something that could have taken months took weeks is sort of what I'm hearing.
- 36:24SPEAKER_02: Yeah, so in previous times,
- 36:28SPEAKER_02: We wouldn't have even bothered doing this,
- 36:30SPEAKER_02: Craig, because it would have taken us so long to get the approvals.
- 36:33SPEAKER_02: But now we've got a system set up through these amazing national assets
- 36:38SPEAKER_02: that have been stood up with the appropriate approvals.
- 36:42SPEAKER_01: We are now basically at the starting blocks as soon as this for analysis as soon as
- 36:49SPEAKER_01: the questions come about.
- 36:52SPEAKER_00: That's great.
- 36:54SPEAKER_00: And a testament to the hard work of yourself and your team.
- 36:59SPEAKER_01: Well, it's taken a village, Craig.
- 37:02SPEAKER_00: Yeah.
- 37:03SPEAKER_00: Yeah, no, it's excellent.
- 37:04SPEAKER_00: I'm glad to be a sort of a tangential part of that village over in WA.
- 37:12SPEAKER_01: Not just tangential, Craig.
- 37:15SPEAKER_00: So just sort of looping back to the Zoladex issue specifically,
- 37:20SPEAKER_00: so AstraZeneca's response,
- 37:22SPEAKER_00: they sort of made the initial decision and then there was a bit of a change
- 37:25SPEAKER_00: of direction,
- 37:26SPEAKER_00: I'm assuming due to advocacy and some pressure,
- 37:29SPEAKER_00: and they've come up with a free access program.
- 37:33SPEAKER_00: Monica,
- 37:34SPEAKER_00: tell us a bit about that and whether that is a viable solution or whether we need
- 37:38SPEAKER_00: to be thinking beyond that.
- 37:40SPEAKER_03: Look, I think as you say that it certainly was a response,
- 37:45SPEAKER_03: I think, to the response of the public and the medical community to their decisions.
- 37:51SPEAKER_03: So initially they announced a free access program for Zolidex for six months.
- 37:57SPEAKER_03: And then I think obviously the feedback to that was that
- 38:00SPEAKER_03: that was nowhere near long enough because most women who need this medication
- 38:04SPEAKER_03: for breast cancer treatment should be on it for five years.
- 38:08SPEAKER_03: Then be left without any options for four and a half years.
- 38:10SPEAKER_03: And they sort of updated that to indefinite supply if there were no other medicines available.
- 38:17SPEAKER_03: I think it's very much a stopgap, you know, from the way that it's been rolled out.
- 38:22SPEAKER_03: It's definitely been very reactionary to,
- 38:25SPEAKER_03: you know, the publicity that they've received and all the advocacy efforts.
- 38:31SPEAKER_03: I think that without the more recent decision around tryptarelin,
- 38:35SPEAKER_03: it wouldn't be the best option possible.
- 38:38SPEAKER_03: Out of lots of bad options that we would have had,
- 38:41SPEAKER_03: but I certainly hope that it's not a precedent that will happen again
- 38:45SPEAKER_03: with other essential cancer medicines.
- 38:50SPEAKER_02: And I think the one thing is that
- 38:56SPEAKER_02: the company has withdrawn
- 38:58SPEAKER_01: the medicine from
- 38:59SPEAKER_01: the PBAC,
- 39:00SPEAKER_01: so it begs the question,
- 39:04SPEAKER_01: They're standing up the access program,
- 39:07SPEAKER_01: but what's to say that the mind of the company won't change early on?
- 39:14SPEAKER_01: So I don't want to sound negative,
- 39:17SPEAKER_01: but it goes without saying,
- 39:19SPEAKER_01: you know, past behavior is going to predict future behavior.
- 39:22SPEAKER_01: And if it's a commercial decision,
- 39:24SPEAKER_01: surely supplying it for free is is a less commercially viable option
- 39:30SPEAKER_01: than getting some funding for it on the PBS, right?
- 39:36SPEAKER_00: It seems like it.
- 39:37SPEAKER_00: And I haven't looked into the status of this drug from an IP point of view,
- 39:41SPEAKER_00: but is it still under patent?
- 39:43SPEAKER_03: It's not.
- 39:44SPEAKER_03: It's actually been around for a long time.
- 39:45SPEAKER_03: There are a number of generic alternatives available,
- 39:48SPEAKER_03: which I believe are in use overseas,
- 39:51SPEAKER_03: but I don't believe any of those manufacturers have put in a PDAC submission.
- 39:56SPEAKER_00: Okay.
- 39:57SPEAKER_00: So is that one option where the PBAC could be a bit more proactive potentially
- 40:02SPEAKER_00: to approach some of those generics to see if they would be interested?
- 40:07SPEAKER_03: From my perspective, that would be a great option.
- 40:10SPEAKER_00: Yeah.
- 40:12SPEAKER_00: I guess, yeah,
- 40:13SPEAKER_00: from a commercial point of view,
- 40:14SPEAKER_00: maybe it's not that attractive if you're talking about,
- 40:16SPEAKER_00: you know, our share of the global market being quite small.
- 40:19SPEAKER_00: Yeah, interesting.
- 40:21SPEAKER_00: Yeah.
- 40:22SPEAKER_02: But, you know,
- 40:23SPEAKER_02: this is potentially we're going back to the HTA review we were talking about in
- 40:27SPEAKER_02: that horizon scanning approach and being proactive on those things.
- 40:32SPEAKER_01: Maybe that's an example of the kinds of things that they're now talking about
- 40:40SPEAKER_01: in terms of stepping in and literally requesting companies to apply, right?
- 40:45SPEAKER_00: Mm-hmm.
- 40:46SPEAKER_00: Yeah.
- 40:48SPEAKER_00: And apart from tryptoralin as an alternative,
- 40:53SPEAKER_00: is there anything like I know that there was the talk about a potential implant
- 40:57SPEAKER_00: that could be another solution.
- 40:59SPEAKER_00: Would that work?
- 41:03SPEAKER_03: So all of these drugs, GnRH agonists, are implants.
- 41:07SPEAKER_03: So they come in one monthly implant or in the case of Zolidex,
- 41:11SPEAKER_03: they're available as three monthly implants.
- 41:13SPEAKER_03: And it's the same medicine that's delivered very slowly over the duration of
- 41:18SPEAKER_03: when it's supposed to be active.
- 41:19SPEAKER_03: So again,
- 41:21SPEAKER_03: we go back to the gender equity issue that for Zolidex,
- 41:24SPEAKER_03: only the one monthly implant was available for women.
- 41:29SPEAKER_03: And I think ideally you'd want to have both options available so that women have
- 41:33SPEAKER_03: the flexibility of choosing between the two
- 41:35SPEAKER_03: because there are some clinical indications where a monthly implant is preferable.
- 41:40SPEAKER_03: So for example,
- 41:41SPEAKER_03: if someone's getting For example,
- 41:45SPEAKER_03: four months of chemotherapy for lymphoma,
- 41:48SPEAKER_03: we often give them Zolidex to,
- 41:50SPEAKER_03: as I've described to patients, put their ovaries to sleep during the chemotherapy.
- 41:54SPEAKER_03: And this is actually quite protective because it helps to prevent early menopause
- 41:58SPEAKER_03: and loss of fertility after chemotherapy.
- 42:01SPEAKER_03: And in that situation,
- 42:02SPEAKER_03: you sort of want to have something like Zolodex administered for
- 42:06SPEAKER_03: the shortest duration possible so that they can have their return
- 42:09SPEAKER_03: of ovarian function as soon as chemotherapy is over.
- 42:12SPEAKER_03: So a one-month implant is ideal,
- 42:14SPEAKER_03: whereas a three-month implant,
- 42:16SPEAKER_03: you're committing a woman to two months of extra ovarian suppression
- 42:20SPEAKER_03: that they don't need.
- 42:21SPEAKER_03: On the other hand,
- 42:22SPEAKER_03: there are women with breast cancer who need to be on these medicines for five years
- 42:26SPEAKER_03: or sometimes even longer.
- 42:27SPEAKER_03: And for them,
- 42:28SPEAKER_03: having a monthly injection at a cancer centre or with their GP is
- 42:32SPEAKER_03: a really big burden on them in terms of time and resources and even the cost of
- 42:37SPEAKER_03: the injections themselves.
- 42:38SPEAKER_03: So having a three-month implant would have been a great option.
- 42:41SPEAKER_03: And with prostate cancer,
- 42:43SPEAKER_03: the implants are available in one-monthly,
- 42:45SPEAKER_03: three-monthly and sometimes even four-monthly formulations.
- 42:48SPEAKER_03: So there is that flexibility there.
- 42:51SPEAKER_03: So I think to answer your question, Craig,
- 42:55SPEAKER_03: switching from Zolidex one monthly to a three monthly implant
- 42:58SPEAKER_03: of another description is one option, but it's not ideal.
- 43:03SPEAKER_03: What I'd love to see is to have both the one monthly and
- 43:05SPEAKER_03: the three monthly formulations available on the PBS,
- 43:08SPEAKER_03: but I don't think that's on the horizon at the moment.
- 43:11SPEAKER_00: Okay.
- 43:12SPEAKER_00: And this is,
- 43:12SPEAKER_00: I guess,
- 43:13SPEAKER_00: where the data monitoring and our systems can really be informative,
- 43:16SPEAKER_00: right, as to what need there is for the different options.
- 43:21SPEAKER_03: Absolutely.
- 43:22SPEAKER_00: Yeah.
- 43:22SPEAKER_00: Okay.
- 43:23SPEAKER_00: So, yeah,
- 43:24SPEAKER_00: just to sort of swing back to data monitoring and our infrastructure to finish off,
- 43:30SPEAKER_00: what lessons have we learned from this and what should our monitoring look like
- 43:34SPEAKER_00: as we go forward?
- 43:37SPEAKER_02: Do you want to start, Monica, and then I can...
- 43:40SPEAKER_03: Yeah.
- 43:41SPEAKER_03: Jump in.
- 43:42SPEAKER_03: I think we've touched on some of the relevant points in the discussion so far.
- 43:48SPEAKER_03: Certainly from a clinician's perspective,
- 43:51SPEAKER_03: I'd love to see the PBAC being more proactive and I guess horizon scanning,
- 43:55SPEAKER_03: as we've mentioned, because as a clinician, we can sort of anticipate that.
- 44:00SPEAKER_03: Things that might occur if there are medicine shortages,
- 44:03SPEAKER_03: if there are other commercial decisions like the ones made around Zolidex
- 44:07SPEAKER_03: and how that's going to impact on patient care.
- 44:13SPEAKER_03: That's my perspective as a clinician.
- 44:17SPEAKER_02: Yeah, and from a population health perspective, Craig, I think there's enormous opportunities.
- 44:25SPEAKER_02: And we kind of touched on this talking about the little case example we used here.
- 44:31SPEAKER_02: But, you know, at a systems perspective, there's enormous benefit in health.
- 44:39SPEAKER_01: Modeling once there's some idea about a potential shortage or withdrawal as
- 44:45SPEAKER_01: an extreme shortage, as I said earlier, and establishing what that might look like.
- 44:52SPEAKER_02: And I know there's great work that is going on within government to do that.
- 44:56SPEAKER_02: But also where I think academics
- 45:00SPEAKER_02: and scientists sitting outside government can really help is You can start thinking
- 45:06SPEAKER_02: about monitoring treatment continuity and switching patterns and what this kind
- 45:15SPEAKER_02: of intervention as in...
- 45:19SPEAKER_02: This period looks like in terms of what is going on with clinician behavior
- 45:24SPEAKER_02: and patient behavior,
- 45:26SPEAKER_02: track whether patients are
- 45:28SPEAKER_01: experiencing delays in therapy,
- 45:30SPEAKER_01: for example, assess impacts
- 45:33SPEAKER_01: on their utilization.
- 45:35SPEAKER_01: Investigations and so on.
- 45:39SPEAKER_01: And then you can evaluate particular groups that might be affected.
- 45:43SPEAKER_01: And this is where Australian data comes into its own in terms of rural patients,
- 45:51SPEAKER_01: younger people,
- 45:52SPEAKER_01: people in disadvantaged populations,
- 45:57SPEAKER_01: who is disproportionately affected by this kind of shock
- 46:04SPEAKER_02: And that's the kind of stuff that we have complete capacity to do
- 46:09SPEAKER_01: now.
- 46:13SPEAKER_01: So it's really important for us to get a sense of what's going on,
- 46:18SPEAKER_01: both at the top line level,
- 46:20SPEAKER_01: but also for population subgroups who may be disproportionately affected by
- 46:26SPEAKER_01: a policy shock or a withdrawal like this.
- 46:30SPEAKER_00: Yeah, I think that's where the responsiveness of our System
- 46:34SPEAKER_00: and our data capabilities is really crucial, isn't it?
- 46:37SPEAKER_00: Absolutely.
- 46:38SPEAKER_00: Yeah.
- 46:39SPEAKER_00: Well, I think that's been a fantastic conversation.
- 46:42SPEAKER_00: I've really enjoyed hearing both of your perspectives and wisdom on this topic.
- 46:47SPEAKER_00: And I know listeners will as well.
- 46:48SPEAKER_00: So I appreciate you making the time in your busy schedules.
- 46:51SPEAKER_00: Thanks, Craig.
- 46:52SPEAKER_00: Yeah.
- 46:53SPEAKER_00: And we're looking forward
- 46:55SPEAKER_00: to bringing people hopefully further conversations like this in the future.
- 46:59SPEAKER_00: All the best.
- 47:03SPEAKER_03: The Meaning of Health is produced at the University of Western Australia with
- 47:06SPEAKER_03: the support of the School of Population and Global Health,
- 47:09SPEAKER_03: the Digital Development and Enhancement Team and the Infrastructure
- 47:12SPEAKER_03: and Platforms Team.
- 47:14SPEAKER_03: The podcast is produced and hosted by Craig Cumming,
- 47:16SPEAKER_03: Courtney Webber, Leah Roberts, Ingrid Stacey and Dorinda Tahar.
- 47:20SPEAKER_03: Music, mixing and post-production is done by Craig Cumming.
- 47:24SPEAKER_03: You can find more information about us at our website, meaningofhealth.com.au.
- 47:29SPEAKER_03: If you would like to get in touch with us,
- 47:31SPEAKER_03: you can email us at meaningofhealthatoutlook.com and contact us on Instagram
- 47:37SPEAKER_03: or bluesky at healthmeanswhat or find us on Facebook or LinkedIn by searching for
- 47:42SPEAKER_03: The Meaning of Health.